Der CHMP empfiehlt die Zulassung von TECVAYLI®▼ (teclistamab) von Johnson & Johnson zur Behandlung des rezidivierten bzw. refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie
BEERSE, BELGIEN, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, ein weltweit führendes Unternehmen im Bereich des multiplen Myeloms, gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) die Zulassung einer Indikationserweiterung für TECVAYLI ® (teclistamab…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Rocket Software Named as a Major Player in IDC MarketScape® for Intelligent Content Services
- GuardianVets Surpasses 2.5 Million After-Hours Veterinary Cases, Highlighting the Growing Need for 24/7 Client Access
- Funnel enters a new era as multifamily’s first front-office-only AI platform
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →